Close Menu

Quidel

The GenomeWeb Index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month.

The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.

The firm's rapid immunoassay revenues jumped ninefold due to more than $587 million in sales of SARS-CoV-2 viral antigen tests.

The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month, with Fulgent, Genetron, and Quidel leading the way.

The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.

Quidel reported preliminary fourth quarter revenues of $808 million to $810 million, compared to $152.2 million in Q4 2019.

The Solana SARS-CoV-2 test can be run in batches of 11 samples, with minimum hands on time, no extraction, and results in approximately 25 minutes.

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all swung up on positive coronavirus vaccine news.

An analysis suggests rapid SARS-CoV-2 tests may have drawbacks under real-world conditions, the New York Times reports.

Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.